320 related articles for article (PubMed ID: 22652532)
61. Routine TP53 testing for breast cancer under age 30: ready for prime time?
McCuaig JM; Armel SR; Novokmet A; Ginsburg OM; Demsky R; Narod SA; Malkin D
Fam Cancer; 2012 Dec; 11(4):607-13. PubMed ID: 22851211
[TBL] [Abstract][Full Text] [Related]
62. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
[TBL] [Abstract][Full Text] [Related]
63. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics.
Zuradelli M; Peissel B; Manoukian S; Zaffaroni D; Barile M; Pensotti V; Cavallari U; Masci G; Mariette F; Benski AC; Santoro A; Radice P
Breast Cancer Res Treat; 2010 Nov; 124(1):251-8. PubMed ID: 20373018
[TBL] [Abstract][Full Text] [Related]
64. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
65. Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
Karppinen SM; Barkardottir RB; Backenhorn K; Sydenham T; Syrjäkoski K; Schleutker J; Ikonen T; Pylkäs K; Rapakko K; Erkko H; Johannesdottir G; Gerdes AM; Thomassen M; Agnarsson BA; Grip M; Kallioniemi A; Kere J; Aaltonen LA; Arason A; Møller P; Kruse TA; Borg A; Winqvist R
J Med Genet; 2006 Nov; 43(11):856-62. PubMed ID: 16825437
[TBL] [Abstract][Full Text] [Related]
66. Recurrent TP53 missense mutation in cancer patients of Arab descent.
Zick A; Kadouri L; Cohen S; Frohlinger M; Hamburger T; Zvi N; Plaser M; Avital E; Breuier S; Elian F; Salah A; Goldberg Y; Peretz T
Fam Cancer; 2017 Apr; 16(2):295-301. PubMed ID: 27866339
[TBL] [Abstract][Full Text] [Related]
67. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Thompson ER; Rowley SM; Li N; McInerny S; Devereux L; Wong-Brown MW; Trainer AH; Mitchell G; Scott RJ; James PA; Campbell IG
J Clin Oncol; 2016 May; 34(13):1455-9. PubMed ID: 26786923
[TBL] [Abstract][Full Text] [Related]
68. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families.
Clague J; Wilhoite G; Adamson A; Bailis A; Weitzel JN; Neuhausen SL
PLoS One; 2011; 6(9):e25632. PubMed ID: 21980511
[TBL] [Abstract][Full Text] [Related]
69. Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2.
Huusko P; Castrén K; Launonen V; Soini Y; Pääkkönen K; Leisti J; Vähäkangas K; Winqvist R
Cancer Genet Cytogenet; 1999 Jul; 112(1):9-14. PubMed ID: 10432928
[TBL] [Abstract][Full Text] [Related]
70. Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
Van Heetvelde M; Van Bockstal M; Poppe B; Lambein K; Rosseel T; Atanesyan L; Deforce D; Van Den Berghe I; De Leeneer K; Van Dorpe J; Vral A; Claes KBM
Cancer Lett; 2018 Jul; 425():125-133. PubMed ID: 29580810
[TBL] [Abstract][Full Text] [Related]
71. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients.
DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N
Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868
[TBL] [Abstract][Full Text] [Related]
72. BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Wiener D; Gajardo-Meneses P; Ortega-Hernández V; Herrera-Cares C; Díaz S; Fernández W; Cornejo V; Gamboa J; Tapia T; Alvarez C; Carvallo P
Breast Cancer Res Treat; 2015 Oct; 153(3):669-78. PubMed ID: 26395808
[TBL] [Abstract][Full Text] [Related]
73. Double heterozygous pathogenic variants in the BRCA1 and BRCA2 genes in a patient with bilateral metachronous breast cancer.
Mampel A; Sottile ML; Denita-Juárez SP; Vargas AL; Vargas-Roig LM
Cancer Genet; 2022 Jan; 260-261():14-17. PubMed ID: 34801929
[TBL] [Abstract][Full Text] [Related]
74. Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian families with high risk of breast cancer.
Guénard F; Labrie Y; Ouellette G; Beauparlant CJ; Durocher F;
J Hum Genet; 2009 Mar; 54(3):152-61. PubMed ID: 19197335
[TBL] [Abstract][Full Text] [Related]
75. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Shakya R; Szabolcs M; McCarthy E; Ospina E; Basso K; Nandula S; Murty V; Baer R; Ludwig T
Proc Natl Acad Sci U S A; 2008 May; 105(19):7040-5. PubMed ID: 18443292
[TBL] [Abstract][Full Text] [Related]
76. Translational advances regarding hereditary breast cancer syndromes.
Gage M; Wattendorf D; Henry LR
J Surg Oncol; 2012 Apr; 105(5):444-51. PubMed ID: 22441895
[TBL] [Abstract][Full Text] [Related]
77. Molecular Analysis of BRCA1 in Human Breast Cancer Cells Under Oxidative Stress.
Gilmore BL; Liang Y; Winton CE; Patel K; Karageorge V; Varano AC; Dearnaley W; Sheng Z; Kelly DF
Sci Rep; 2017 Mar; 7():43435. PubMed ID: 28262780
[TBL] [Abstract][Full Text] [Related]
78. Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of BRCA1?
Martin AM; Kanetsky PA; Amirimani B; Colligon TA; Athanasiadis G; Shih HA; Gerrero MR; Calzone K; Rebbeck TR; Weber BL
J Med Genet; 2003 Apr; 40(4):e34. PubMed ID: 12676907
[No Abstract] [Full Text] [Related]
79. Hereditary breast cancer: the era of new susceptibility genes.
Apostolou P; Fostira F
Biomed Res Int; 2013; 2013():747318. PubMed ID: 23586058
[TBL] [Abstract][Full Text] [Related]
80. Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Singhal D; Hahn CN; Feurstein S; Wee LYA; Moma L; Kutyna MM; Chhetri R; Eshraghi L; Schreiber AW; Feng J; Wang PP; Babic M; Parker WT; Gao S; Moore S; Das S; Thomas D; Pattnaik S; Brown AL; D'Andrea RJ; Poplawski NK; Thomas D; Scott HS; Godley LA; Hiwase DK
Leukemia; 2021 Nov; 35(11):3245-3256. PubMed ID: 33850299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
